Genomic Test Could Help Predict Aggressive Disease in Men Newly Diagnosed with Prostate Cancer
An analysis of patient data from across Michigan found scores from the Decipher Biopsy test independently aligned with outcomes
Randy Vince, Jr., M.D., M.S.
Newswise After a biopsy comes back positive for prostate cancer, patients and their doctors are often left with a choice between taking a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation.
And identifying which patients will benefit from more immediate and aggressive treatment isn’t always clear.
A new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan, however, found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of cancer progression.
Genomic test could help predict aggressive disease in men newly diagnosed with prostate cancer
uofmhealth.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uofmhealth.org Daily Mail and Mail on Sunday newspapers.
Genomic test may help identify prostate cancer patients at high risk of disease progression
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Overcoming a newly recognized form of resistance to modern prostate cancer drugs
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
E-Mail
A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients. The findings appear in the March issue of the
Journal of Urology.
The MyProstateScore test, which is being commercialized by LynxDX, a U-M startup company, measures levels of cancer-specific genes in a patient s urine. It is based on U-M research that discovered that half of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG relocate on a chromosome and fuse together creating an on-switch for prostate cancer development.